Study of Cerebral Vascular Reserve Using Pharmacological Testing With Acetazolamide: A Non-Inferiority Study of PET Method Compared to Conventional Reference Scintigraphy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-10-31

Study Completion Date

2026-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study compares two methods for assessing brain blood flow. PET scan will be use with a drug called Acetazolamide and compare its effectiveness to the standard scintigraphy method. The goal is to see if the PET scan is just as good as the traditional method in measuring how well the brain's blood vessels respond to the drug.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

CANF-Comb-II PET-MR in Atherosclerosis Multisite

NCT05838547

Carotid Atherosclerosis Asymptomatic Carotid Artery Stenosis Carotid Artery Atheroma

RECRUITING

PET Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis

NCT02417688

Carotid Atherosclerosis

COMPLETED PHASE1

PET Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis (Volunteer - BioD and Safety Study)

NCT02498379

Atherosclerosis

COMPLETED EARLY_PHASE1

Registry Study of Cerebral Small Vessel Disease

NCT07342075

Cerebral Small Vessel Diseases Cognitive Impairment Diffusion Tensor Imaging

RECRUITING

Imaging the Pathogenesis of Cerebral Small Vessel Disease

NCT05703386

Ischemic Stroke Hypertension Hyperlipidemias +1 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebrovascular Circulation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental Arms

Group Type EXPERIMENTAL

PET scan

Intervention Type DIAGNOSTIC_TEST

18F-FDG PET scans will be performed to assess cerebral vascular reserve. For exams involving stimulation with Acetazolamide (DIAMOX®), the radiopharmaceutical injection (18F-FDG or 99mTc-HMPAO) will start exactly 15 minutes after the Acetazolamide (DIAMOX®) injection.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PET scan

18F-FDG PET scans will be performed to assess cerebral vascular reserve. For exams involving stimulation with Acetazolamide (DIAMOX®), the radiopharmaceutical injection (18F-FDG or 99mTc-HMPAO) will start exactly 15 minutes after the Acetazolamide (DIAMOX®) injection.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Chronic stenosing cerebral vascular pathology (stenosis \> 70% on Doppler examination or angiography).
* Patient aged over 18 years.
* Patient who has voluntarily agreed to participate in the study and has signed the written informed consent.
* Patient affiliated with a social security system.

Exclusion Criteria

* Patient with stenosis less than 70% on Doppler examination or angiography.
* Patient with a contraindication to 18F-FDG PET examinations: severe claustrophobia, poorly controlled diabetes during 18F-FDG PET examinations (fasting capillary blood glucose ≥ 11 mmol/L).
* Patient with a contraindication to scintigraphy.
* Patient with an allergy to sulfonamides (Acetazolamide DIAMOX®).
* Patient enrolled in another clinical study with a specified exclusion period.
* Minor patient.
* Patient unable to give informed consent.
* Vulnerable individuals

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No